Anfarm Hellas S.A. - Main Component
| Active Substance | Strength | Form |
|---|---|---|
| TeicoplaninUnder Development | 200 mg & 400 mg/vial | Pd.Sol.Inf |
| Tenoxicam | 20mg/Vial | Ps.Inj.Sol |
| Tenoxicam | 20mg | F.C.Tab |
| Tigecycline | 50mg/Vial | Pd.Sol.Inf |
| Active Substance | Strength | Form |
|---|---|---|
| TeicoplaninUnder Development | 200 mg & 400 mg/vial | Pd.Sol.Inf |
| Tenoxicam | 20mg/Vial | Ps.Inj.Sol |
| Tenoxicam | 20mg | F.C.Tab |
| Tigecycline | 50mg/Vial | Pd.Sol.Inf |
| Active Substance | Strength | Form | Market Availability |
|---|---|---|---|
| TeicoplaninUnder Development | 200 mg & 400 mg/vial | Pd.Sol.Inf | Q1 2023 |
| Tenoxicam | 20mg/Vial | Ps.Inj.Sol | International |
| Tenoxicam | 20mg | F.C.Tab | Selected Markets |
| Tigecycline | 50mg/Vial | Pd.Sol.Inf | International |
